American Outdoor Brands Corporation (NASDAQ:AOBC) represented a move of 5.6 percent or $-0.61 per share and closed its previous day trading session at $10.74. 1.38 Million Shares were traded in the last trading session with an Average Volume of 1.64 Million Shares. The stock currently has a Market Capitalization of 605.41 Million.
American Outdoor Brands Corporation is a manufacturer and seller of firearms and accessory products for the shooting, hunting and outdoor enthusiast. The company’s product comprises pistols, revolvers, rifles, guns, handcuffs and firearm-related products and accessories. It sells its products under the brand name Smith & Wesson, M&P, Thompson/Centre and Performance Centre. American Outdoor Brands Corporation, formerly known as Smith & Wesson Holding Corporation, is based in Springfield, Massachusetts.
The stock traded between $ 9.82 and $24.49 over 1-Year time period showing its price to sales ratio of 0.82. American Outdoor Brands Corporation (NASDAQ:AOBC) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a INCREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-14.11 and 200-Day Simple Moving Average of $-36.93. Its Price to Free Cash Flow is 19.47 and Price to Book of 1.46.
Analyst’s recommended the stock as 2.1 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, American Outdoor Brands Corporation (NASDAQ:AOBC) reported its Actual EPS of $0.11/share. The analysts offering Earnings Estimates for the company were believing that American Outdoor Brands Corporation could bring EPS of $0.07/share. The difference between Actual EPS and Estimated EPS was 0.04 Percent. Thus showing an Earnings Surprise of 57.1 Percent.
CorMedix, Inc. (NYSE:CRMD)
In the last trading session, CorMedix, Inc. (NYSE:CRMD) added its value by 8.24% closing at the price of $0.56. The stock currently has market capitalization of 38.93 Million, with average volume of 998.29 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently CorMedix, Inc. (NYSE:CRMD) is showing beta of 0.25. This particular value of beta suggests that CorMedix, Inc. (NYSE:CRMD) has historically moved 25% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for CorMedix, Inc. (NYSE:CRMD) is at $-0.61.
The stock currently has RSI of 63.87. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
CorMedix Inc. is a development-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedix’s goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications. The Company’s therapeutic candidates for cardiorenal disease may be small molecules, biologicals, devices and/or diagnostics (tests) that enable therapy. Its product pipeline includes: CRMD001, a unique formulation Deferiprone which is in development to prevent Contrast-Induced Acute Kidney Injury and to slow progression of Chronic Kidney Disease; CRMD002, a diagnostic test for urinary labile iron; CRMD003 (Neutrolin(r), an antimicrobial/anticoagulant solution) is in development to prevent Catheter Related Bloodstream Infection; CRMD004, a pressure sensitive gel which has many uses, including extending the benefits of Neutrolin(r). CorMedix Inc. is based in Summit, New Jersey.
CorMedix, Inc. (NYSE:CRMD) topped its 52-week high price of $2.360 on 02/21/17 and 52-Week Low Price of $0.320 on 08/14/17. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 12.23% and monthly volatility of 8.43% respectively.